Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity
<h3>Objective</h3><p dir="ltr">Detailed proteomic analysis in a cohort of patients with differing severity of COVID-19 disease identified biomarkers within the complement and coagulation cascades as biomarkers for disease severity has been reported; however, it is unclear...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513517665648640 |
|---|---|
| author | Abu Saleh Md Moin (6189512) |
| author2 | Ahmed Al-Qaissi (9975173) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| author2_role | author author author author |
| author_facet | Abu Saleh Md Moin (6189512) Ahmed Al-Qaissi (9975173) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| author_role | author |
| dc.creator.none.fl_str_mv | Abu Saleh Md Moin (6189512) Ahmed Al-Qaissi (9975173) Thozhukat Sathyapalan (704787) Stephen L. Atkin (6684368) Alexandra E. Butler (6189536) |
| dc.date.none.fl_str_mv | 2021-06-25T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3389/fendo.2021.658304 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Type_2_Diabetes_Coagulopathy_Proteins_May_Conflict_With_Biomarkers_Reflective_of_COVID-19_Severity/25713819 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences type 2 diabetes hypoglycemia COVID-19 biomarkers proteomics |
| dc.title.none.fl_str_mv | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Objective</h3><p dir="ltr">Detailed proteomic analysis in a cohort of patients with differing severity of COVID-19 disease identified biomarkers within the complement and coagulation cascades as biomarkers for disease severity has been reported; however, it is unclear if these proteins differ sufficiently from other conditions to be considered as biomarkers.</p><h3>Methods</h3><p dir="ltr">A prospective, parallel study in T2D (n = 23) and controls (n = 23). A hyperinsulinemic clamp was performed and normoglycemia induced in T2D [4.5 ± 0.07 mmol/L (81 ± 1.2 mg/dl)] for 1-h, following which blood glucose was decreased to ≤2.0 mmol/L (36 mg/dl). Proteomic analysis for the complement and coagulation cascades were measured using Slow Off-rate Modified Aptamer (SOMA)-scan.</p><h3>Results</h3><p dir="ltr">Thirty-four proteins were measured. At baseline, 4 of 18 were found to differ in T2Dversuscontrols for platelet degranulation [Neutrophil-activating peptide-2 (p = 0.014), Thrombospondin-1 (p = 0.012), Platelet factor-4 (p = 0.007), and Kininogen-1 (p = 0.05)], whilst 3 of 16 proteins differed for complement and coagulation cascades [Coagulation factor IX (p < 0.05), Kininogen-1 (p = 0.05), and Heparin cofactor-2 (p = 0.007)]; STRING analysis demonstrated the close relationship of these proteins to one another. Induced euglycemia in T2D showed no protein changesversusbaseline. At hypoglycemia, however, four proteins changed in controls from baseline [Thrombospondin-1 (p < 0.014), platelet factor-4 (p < 0.01), Platelet basic protein (p < 0.008), and Vitamin K-dependent protein-C (p < 0.00003)], and one protein changed in T2D [Vitamin K-dependent protein-C, (p < 0.0002)].</p><h3>Conclusion</h3><p dir="ltr">Seven of 34 proteins suggested to be biomarkers of COVID-19 severity within the platelet degranulation and complement and coagulation cascades differed in T2Dversuscontrols, with further changes occurring at hypoglycemia, suggesting that validation of these biomarkers is critical. It is unclear if these protein changes in T2D may predict worse COVID-19 disease for these patients.</p><h3>Clinical Trial Registration</h3><p dir="ltr">https://clinicaltrials.gov/, identifier NCT03102801.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Endocrinology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fendo.2021.658304" target="_blank">https://dx.doi.org/10.3389/fendo.2021.658304</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0a8e31fa4d618f02810c3ec9c124534f |
| identifier_str_mv | 10.3389/fendo.2021.658304 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25713819 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 SeverityAbu Saleh Md Moin (6189512)Ahmed Al-Qaissi (9975173)Thozhukat Sathyapalan (704787)Stephen L. Atkin (6684368)Alexandra E. Butler (6189536)Biomedical and clinical sciencesClinical sciencestype 2 diabeteshypoglycemiaCOVID-19biomarkersproteomics<h3>Objective</h3><p dir="ltr">Detailed proteomic analysis in a cohort of patients with differing severity of COVID-19 disease identified biomarkers within the complement and coagulation cascades as biomarkers for disease severity has been reported; however, it is unclear if these proteins differ sufficiently from other conditions to be considered as biomarkers.</p><h3>Methods</h3><p dir="ltr">A prospective, parallel study in T2D (n = 23) and controls (n = 23). A hyperinsulinemic clamp was performed and normoglycemia induced in T2D [4.5 ± 0.07 mmol/L (81 ± 1.2 mg/dl)] for 1-h, following which blood glucose was decreased to ≤2.0 mmol/L (36 mg/dl). Proteomic analysis for the complement and coagulation cascades were measured using Slow Off-rate Modified Aptamer (SOMA)-scan.</p><h3>Results</h3><p dir="ltr">Thirty-four proteins were measured. At baseline, 4 of 18 were found to differ in T2Dversuscontrols for platelet degranulation [Neutrophil-activating peptide-2 (p = 0.014), Thrombospondin-1 (p = 0.012), Platelet factor-4 (p = 0.007), and Kininogen-1 (p = 0.05)], whilst 3 of 16 proteins differed for complement and coagulation cascades [Coagulation factor IX (p < 0.05), Kininogen-1 (p = 0.05), and Heparin cofactor-2 (p = 0.007)]; STRING analysis demonstrated the close relationship of these proteins to one another. Induced euglycemia in T2D showed no protein changesversusbaseline. At hypoglycemia, however, four proteins changed in controls from baseline [Thrombospondin-1 (p < 0.014), platelet factor-4 (p < 0.01), Platelet basic protein (p < 0.008), and Vitamin K-dependent protein-C (p < 0.00003)], and one protein changed in T2D [Vitamin K-dependent protein-C, (p < 0.0002)].</p><h3>Conclusion</h3><p dir="ltr">Seven of 34 proteins suggested to be biomarkers of COVID-19 severity within the platelet degranulation and complement and coagulation cascades differed in T2Dversuscontrols, with further changes occurring at hypoglycemia, suggesting that validation of these biomarkers is critical. It is unclear if these protein changes in T2D may predict worse COVID-19 disease for these patients.</p><h3>Clinical Trial Registration</h3><p dir="ltr">https://clinicaltrials.gov/, identifier NCT03102801.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Endocrinology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fendo.2021.658304" target="_blank">https://dx.doi.org/10.3389/fendo.2021.658304</a></p>2021-06-25T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3389/fendo.2021.658304https://figshare.com/articles/journal_contribution/Type_2_Diabetes_Coagulopathy_Proteins_May_Conflict_With_Biomarkers_Reflective_of_COVID-19_Severity/25713819CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257138192021-06-25T03:00:00Z |
| spellingShingle | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity Abu Saleh Md Moin (6189512) Biomedical and clinical sciences Clinical sciences type 2 diabetes hypoglycemia COVID-19 biomarkers proteomics |
| status_str | publishedVersion |
| title | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| title_full | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| title_fullStr | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| title_full_unstemmed | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| title_short | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| title_sort | Type 2 Diabetes Coagulopathy Proteins May Conflict With Biomarkers Reflective of COVID-19 Severity |
| topic | Biomedical and clinical sciences Clinical sciences type 2 diabetes hypoglycemia COVID-19 biomarkers proteomics |